Nvidia and Eli Lilly have announced a joint investment of up to $1 billion over the next five years to establish an AI co-innovation lab in the San Francisco Bay Area. The facility aims to integrate artificial intelligence into biomedical research and drug discovery processes by utilizing co-located teams from both organizations.
The lab will leverage Nvidia’s BioNeMo platform and the upcoming Vera Rubin chip architecture to train foundation models focused on biology and chemistry. These systems are designed to learn molecular and protein structures, facilitating a continuous learning loop that integrates robotics and physical AI for 24/7 experimentation and manufacturing.
This partnership expands on a 2025 collaboration where the companies deployed a supercomputer for Eli Lilly equipped with over 1,000 Grace Blackwell GPUs. The initiative represents a strategic shift for Nvidia, moving from hardware supply to embedding its technology directly into the research workflows of pharmaceutical giants.
Beyond the corporate venture, Nvidia is participating in the Genesis Mission, a public-private initiative with the US Department of Energy launched in late 2025. This project focuses on enhancing AI infrastructure, digital twins, and open-source models to increase the productivity of American scientific research across sectors like energy and national security.
